Arryhthmia-induced cardiomyopathies
Conditions
Interventions
Group 1: Patients with Arryhthmia-induced cardiomyopathies
Sponsors
Universitätsklinikum Jena
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: ->Inpatient treatment for heart failure with suspected arrhythmia-induced cardiomyopathy ->Atrial fibrillation / persistent supraventricular tachycardia, frequent ventricular extrasystoles (presumably newly onset within the last 3 months) ->Left ventricular function = 50% (HFrEF / HFmrEF)
Exclusion criteria
Exclusion criteria: ->Age Special patient groups ->Chronically non-consenting patients ->Acutely non-consenting patients ->Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of arrhythmia-induced cardiomyopathy (AI-CMP) in patients with newly diagnosed arrhythmia (e.g., atrial fibrillation, premature ventricular complexes, atrial flutter), defined as newly developed systolic dysfunction (left ventricular ejection fraction [LVEF] <50%) in the absence of other structural heart disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of potential predictors for AI-CMP (demographic, echocardiographic, electrocardiographic, and laboratory parameters) Analysis of LVEF changes following therapeutic interventions Time interval between arrhythmia diagnosis and onset of AI-CMP Longitudinal changes in biomarkers and imaging parameters, including NT-proBNP, TAPSE, QRS duration, and global longitudinal strain (GLS) | — |
Countries
Germany
Contacts
Public ContactRalf Surber
Universitätsklinikum Jena
Outcome results
None listed